keyword
MENU ▼
Read by QxMD icon Read
search

azathioprine crohn

keyword
https://www.readbyqxmd.com/read/28175127/p536-combination-therapy-of-bone-marrow-mesenchymal-stromal-cells-and-azathioprine-not-affect-the-clinical-course-luminal-crohn-s-disease
#1
O Knyazev, A Parfenov, N Fadeeva, A Konoplyannikov, A Kagramanova, I Ruchkina
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174997/p119-higher-levels-of-infliximab-may-alleviate-the-need-of-azathioprine-comedication-in-the-treatment-of-patients-with-crohn-s-disease-a-sonic-post-hoc-analysis
#2
J-F Colombel, O J Adedokun, C Gasink, K Tang, F Cornillie, G D'Haens, P Rutgeerts, W Reinisch, W Sandborn, S Hanauer
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174954/dop071-comparison-of-endoscopic-responses-to-adalimumab-monotherapy-and-combination-therapy-with-azathioprine-in-patients-with-crohn-s-disease-a-sub-analysis-of-diamond-trial
#3
K Watanabe, T Matsumoto, S Motoya, T Hisamatsu, H Nakase, N Yoshimura, T Ishida, S Kato, T Nakagawa, M Nagahori, M Esaki, T Matsui, Y Naito, T Kanai, Y Suzuki, M Nojima, M Watanabe, T Hibi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172958/p394-prolonged-azathioprine-treatment-reduces-the-need-for-surgery-in-early-crohn-s-disease
#4
Y Qiu, R Mao, S-H Zhang, R Feng, Z-R Zeng, M-H Chen
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172953/p564-low-dose-azathioprine-improves-long-term-efficacy-of-infliximab-maintenance-treatment-in-japanese-patients-with-crohn-s-disease
#5
M Nasuno, S Motoya, K Sugiyama, M Miyakawa, H Tanaka, T Iida, K Onodera, H Nakase
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28160250/thiopurines-and-methotrexate-use-in-ibd-patients-in-a-biologic-era
#6
REVIEW
Gerassimos J Mantzaris
Although we have been living in the era of biologic therapy for several decades, the use of immunomodulators (primarily thiopurines [azathioprine and mercaptopurine] and less so methotrexate) still remains an important component of the inflammatory bowel disease (IBD) pharmaceutical arsenal. Thiopurines as monotherapy exert corticosteroid-sparing effects and can maintain long-term remission in a considerable proportion of patients who have frequent relapses and are or have become mesalazine and/or corticosteroid intolerant or refractory...
February 3, 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28147380/promises-and-dangers-of-combination-therapy
#7
REVIEW
Wolfgang Kruis, Phuong G Nguyen, Julia Morgenstern
The efficiency of the existing methods of treating inflammatory bowel disease (IBD) is limited. There are 2 ways to address this problem - either create new treatment modalities or optimize current therapies. Optimisation may be accomplished by using combinations of established therapeutic strategies. With regard to topically acting compounds such as 5-aminosalicylic acid, combining oral and rectal preparations is a commonly used method. Another commonly used combination is anti-tumor necrosis factor (TNF)-α antibody modalities together with immunosuppressants (thiopurines, methotrexate)...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28129286/methotrexate-for-refractory-crohn-s-disease-compared-with-thiopurines-a-retrospective-non-head-to-head-controlled-study
#8
Zicheng Huang, Kang Chao, Miao Li, Min Zhi, Jian Tang, Pinjin Hu, Xiang Gao
BACKGROUND: This study assessed the efficacy and safety of methotrexate (MTX) compared with thiopurines (TPs) for refractory Crohn's disease. METHODS: Fifty-one consecutive patients who were refractory or intolerant to TPs and steroid-dependent were retrospectively analyzed. MTX (20 mg/wk, subcutaneous) was adopted for inducing and maintaining clinical remission (CR). Fifty-seven patients who were naive to immunosuppressant and prescribed azathioprine (2 mg·kg·d) or mercaptopurine (1 mg·kg·d) were simultaneously recruited...
January 26, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28093426/oesophageal-presentation-of-crohn-s-disease
#9
Sara Monteiro, Maria João Moreira, José Manuel Ribeiro, José Cotter
Crohn's disease (CD) is characterised by a transmural inflammatory process, which can affect any part of the digestive tract; however, CD with oesophageal presentation is rare. We report a case of a previously healthy young woman with symptoms of dysphagia, odynophagia, chest pain and weight loss, who presented oesophageal ulcers at upper endoscopy and whose histology revealed granulomatous oesophagitis. After complementary study, a mild ileocaecal involvement of CD was demonstrated. The patient became asymptomatic with proton pump inhibitor and a course of prednisolone...
January 16, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28088612/alterations-in-cytokine-gene-expression-profile-in-colon-mucosa-of-inflammatory-bowel-disease-patients-on-different-therapeutic-regimens
#10
Tsvetelina Velikova, Dobroslav Kyurkchiev, Zoya Spassova, Iliya Karakolev, Ekaterina Ivanova-Todorova, Iskra Altankova, Spaska Stanilova
Inflammatory bowel disease (IBD) is assumed to be caused by genetic and environmental factors that interact together in promoting intestinal immune dysregulation where cytokines have validated role. However, the underlying intimate mechanisms in the human IBD involving cytokines still needs to be supplemented especially in the clinical context. The aim of this study was to investigate the expression of some inflammatory and regulatory cytokines (IL-17A, IL-23, IL-6, TGFβ1, and IL-10) as well as of the transcription factor FoxP3 in mucosal samples of IBD and non-IBD patients...
January 12, 2017: Cytokine
https://www.readbyqxmd.com/read/28058029/efficacy-of-additional-treatment-with-azathioprine-in-a-patient-with-prednisolone-dependent-gastric-sarcoidosis
#11
Masaki Murata, Mitsushige Sugimoto, Yoshihiro Yokota, Hiromitsu Ban, Osamu Inatomi, Shigeki Bamba, Ryoji Kushima, Akira Andoh
Gastric sarcoidosis with noncaseating granuloma is rare. Although corticosteroid produces a dramatic clinical response, it is unknown whether azathioprine show efficacy in prednisolone-dependent cases. Here, we report a case of gastric sarcoidosis in a 25-year-old man with severe epigastlargia. Gastroendoscopy revealed multiple map-like ulcerations. Histological examination showed multiple noncaseating granulomatous lesions in gastric mucosa, which were incompatible with diagnoses of Crohn's disease or tuberculosis...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28038706/hepatosplenic-t-cell-lymphoma-arising-in-patients-with-immunodysregulatory-disorders-a-study-of-7-patients-who-did-not-receive-tumor-necrosis-factor-%C3%AE-inhibitor-therapy-and-literature-review
#12
Mariko Yabe, L Jeffrey Medeiros, Yahya Daneshbod, Masoud Davanlou, Carlos E Bueso-Ramos, Elisa J Moran, Ken H Young, Roberto N Miranda
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive extranodal T-cell lymphoma that can arise in patients with underlying immune disorders. Others have suggested that tumor necrosis factor (TNF)-α inhibitor therapy for immune disorders increases the risk of HSTCL. To assess for a potential relationship between HSTCL and the use of TNF-α inhibitors, we searched for patients with HSTCL and underlying immune disorders at our institution. We identified 7 patients with a median age of 38 years. Five patients had Crohn disease, 1 ulcerative colitis, and 1 rheumatoid arthritis...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28002129/development-and-internal-validation-of-a-model-using-fecal-calprotectin-in-combination-with-infliximab-trough-levels-to-predict-clinical-relapse-in-crohn-s-disease
#13
Xavier Roblin, Gerard Duru, Nicolas Williet, Emilie Del Tedesco, Murielle Cuilleron, Camille Jarlot, Jean Marc Phelip, Gilles Boschetti, Bernard Flourié, Stephane Nancey, Laurent Peyrin-Biroulet, Stephane Paul
BACKGROUND: The best noninvasive method predicting clinical relapse remains undetermined in infliximab (IFX)-treated patients with Crohn's disease. METHODS: All patients with CD on IFX maintenance treatment and in clinical remission for at least 16 weeks, between 2011 and 2014, were enrolled in a prospective single-center study. The Crohn's Disease Activity Index (CDAI), fecal calprotectin, C-reactive protein levels, antibodies (ATI), and trough level (TLI) of IFX were measured at every IFX infusion...
January 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27933472/tumor-necrosis-factor-alpha-inhibitors-did-not-influence-postoperative-morbidity-after-elective-surgical-resections-in-crohn-s-disease
#14
Paulo Gustavo Kotze, Mansur Paulo Saab, Bárbara Saab, Lorete Maria da Silva Kotze, Marcia Olandoski, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Maria de Lourdes Setsuko Ayrizono, Daniela de Oliveira Magro, Claudio Saddy Rodrigues Coy
BACKGROUND: The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. AIMS: To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy. METHODS: This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded)...
December 8, 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27920658/isolated-bilateral-gastrocnemius-myositis-in-crohn-disease-successfully-treated-with-adalimumab
#15
Salvatore Vadala di Prampero, Marco Marino, Francesco Toso, Claudio Avellini, Vu Nguyen, Dario Sorrentino
Extraintestinal manifestations are common in inflammatory bowel disease; however, muscular involvement in Crohn disease is rarely reported. We present a case of a 26-year-old male with ileocolonic Crohn disease who developed sudden tenderness in both calves. Doppler ultrasound was negative for deep vein thrombosis. Magnetic resonance imaging of the gastrocnemius muscle showed high intensity signal in the muscle fibers, and muscle biopsy demonstrated nonspecific lymphocytic myositis. Other relevant laboratory results included normal antineutrophil cytoplasmic antibodies and creatine kinase as well as elevated C-reactive protein, erythrocyte sedimentation rate, and anti-Saccharomyces cerevisiae IgG titer...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920646/successful-treatment-of-small-intestinal-bleeding-in-a-crohn-s-patient-with-noncirrhotic-portal-hypertension-by-transjugular-portosystemic-shunt-placement-and-infliximab-treatment
#16
Benjamin Heimgartner, Heather Dawson, Andrea De Gottardi, Reiner Wiest, Jan Hendrik Niess
Small intestinal bleeding in Crohn's disease patients with noncirrhotic portal hypertension and partial portal and superior mesenteric vein thrombosis is a life-threatening event. Here, a case is reported in which treatment with azathioprine may have resulted in nodular regenerative hyperplasia, portal hypertension and portal vein thrombosis. The 56-year-old patient with Crohn's disease developed nodular regenerative hyperplasia under treatment with azathioprine. He was admitted with severe bleeding. Gastroscopy showed small esophageal varices without bleeding stigmata...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27896276/the-efficacy-of-infliximab-monotherapy-versus-infliximab-azathioprine-sequential-treatment-in-crohn-s-disease-experience-from-a-tertiary-medical-center-in-china
#17
Tianyu Zhang, Zhengting Wang, Rong Fan, Maochen Zhang, Yun Lin, Liwen Hong, Xiaolin Zhou, Shurong Hu, Mengmeng Cheng, Jie Zhong
Objective. To evaluate the efficacy of infliximab (IFX) monotherapy versus infliximab-azathioprine sequential treatment in Crohn's disease (CD) patients. Methods. Patients newly diagnosed with CD using IFX as induction therapy were enrolled. After 6 times of IFX infusions, they were divided into IFX monotherapy group and IFX-AZA sequential therapy group. Clinical remission rates were assessed at weeks 57, 84, 111, and 138 while endoscopic remission rates were assessed at weeks 84 and 138 to evaluate the efficacy of these two groups...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27882164/inflammatory-bowel-disease-in-chinese-children-a-retrospective-analysis-of-49-cases
#18
Ying Zhou, Ying Huang
To present study reports the clinical characteristics, diagnosis and management of pediatric patients with inflammatory bowel disease (IBD) in China. Clinical records of 49 pediatric patients with IBD at Fudan University Children's Hospital (Shanghai, China) between July 2001 and May 2012 were reviewed. Of 49 patients (30 males and 19 females), 8 patients had ulcerative colitis (UC) and 41 patients had Crohn's disease (CD). The mean age was 10.4 years in patients with UC and 10.1 years in patients with CD. The percentages of patients with UC with abdominal pain, diarrhea or rectal bleeding were 62...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27867692/osteonecrosis-of-both-knees-in-a-woman-with-crohn-s-disease
#19
Mara Barbosa, José Cotter
Osteonecrosis is a very rare complication of Crohn's disease (CD). It is not clear if it is related to corticosteroid therapy or if it occurs as an extraintestinal manifestation of inflammatory bowel disease. We present the case of a patient with CD who presented with osteonecrosis of both knees. A 22 years old woman was diagnosed with CD in April 2012 (Montreal Classification A2L1 + L4B3p). She was started on prednisolone (40 mg/d), azathioprine (100 mg/d) and messalazine (3 g/d). In July 2012, due to active perianal disease, infliximab therapy was initiated...
November 6, 2016: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27864028/anti-tnf-therapy-is-able-to-stabilize-bowel-damage-progression-in-patients-with-crohn-s-disease-a-study-performed-using-the-l%C3%A3-mann-index
#20
Giorgia Bodini, Edoardo G Giannini, Costanza De Maria, Pietro Dulbecco, Manuele Furnari, Elisa Marabotto, Vincenzo Savarino, Edoardo Savarino
AIMS: The Lémann Index (LI) was developed to assess the cumulative structural damage of the intestinal tract in patients with Crohn's Disease (CD) independently of clinical and biochemical activity. Recently, the goal of CD focused on obtaining mucosal healing and deep remission rather than simple symptom control. These new therapeutic aims emphasize the need to prevent progression of bowel damage. In this study we aimed to evaluate the influence of different treatments on structural damage progression, assessed by means of LI in a series of CD patients consistently treated with various drugs...
February 2017: Digestive and Liver Disease
keyword
keyword
30477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"